Summary
The effects of GABA-elevating agents were examined with respect to the cellular compartments in which GABA increases occurred and the brain region(s) that mediate the anticonvulsant activity of these compounds. Changes in GABA occurring in the presence and absence of GABAergic nerve terminals were estimated in vivo using rats in which the GABA projection to the substantia nigra (SN) was destroyed on one side of the brain. One week post-operatively, the GABA concentration in the denervated SN was 10–20% of control. The net increase in GABA content of the denervated SN was compared to that of the intact SN after intraperitoneal injection of amino-oxacetic acid (AOAA), di-n-propylacetate (DPA) and γ-vinyl GABA (GVG). In the intact SN, all drugs produced significant increases in GABA. In the denervated SN, both AOAA and GVG produced marked increases in GABA (nearly equivalent to those obtained in the intact SN) whereas DPA was without effect. It therefore appears that the DPA-induced elevation of GABA depends upon the presence of GABAergic nerve terminals whereas AOAA and GVG primarily elevate GABA in non-nerve terminal compartments. An increase in GABA associated with nerve terminals was obtained with GVG only after a latency of more than 12 h following a single injection. The time course of elevation of nerve terminal-associated GABA coincided with the time course of anticonvulsant action of GVG; both effects were maximal at 60 h after a single injection. Taken together, our results indicate that the ability of DPA, AOAA and GVG to protect against chemically- and electrically-induced seizures is directly correlated with increases in nerve terminal GABA and not related to increases in other GABA compartments.
Localization of the anatomical site that mediates anticonvulsant activity was examined using intracerebral injections of GVG into fore-, mid- and hindbrain areas. Blockade of tonic hindlimb extension in the maximal electroshock test and blockade of tonic and clonic seizures produced by pentylenetetrazol and bicuculline was obtained by microinjection of GVG (10 µg) into the ventral tegmental area of the midbrain. Injections of GVG (10–40 /µg) into forebrain areas (striatum, thalamus) or into hindbrain (pontine tegmentum) were without anticonvulsant activity. Anticonvulsant effects of midbrain GVG were correlated with GABA elevation (3–4 fold) within a 1.5 mm radius of the injection site; these effects were obtained within 6 h and lasted three to four days after a single treatment. After four days seizure activity returned to control. No changes in spontaneous motor activity or reflexes accompanied the GVG injections. Similar but shorter lasting anticonvulsant effects were obtained with the direct GABA receptor agonist muscimol (50 ng) injected into the midbrain site. On the other hand, doses of muscimol up to 500 ng placed in the rostral pontine tegmentum were without anticonvulsant effect, despite the appearance of marked sedation.
The time to peak anticonvulsant activity after midbrain microinjection of GVG (6 h) was considerably more rapid than that after intraperitoneal injection (60 h). Compartmental analysis revealed that nerve terminal associated GABA was elevated by 6 h after GVG when the direct microinjection route was used. These results suggest that GABAergic synapses in the midbrain may be critically involved in the control of seizure propagation.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
DeFeudis, F. V. & Mandel, P., 1981. Amino Acid Neuro-transmitters; Adv. in Biochem. Psychopharmacol. Vol. 29, Raven Press, New York.
Costa, E., Dichiara, G. & Gessa, G. L., 1981. GABA and Benzodiazepine Receptors, Adv. in Biochem. Psychopharmacol. Vol. 26, Raven Press, New York.
Lai, H., 1980. GABA Neurotransmission, Brain Res. Bull. 5: Suppl 2.
Bartholini, G., Scatton, B., Zivkovic, B. & Lloyd, K. G., 1979. GABA-Neurotransmitters (Krogsgaard-Larsen, P., Scheel-Kruger, J. & Kofod, H., eds) Academic Press, New York, pp. 326–334.
Johnston, G. A. R., Allan, R. D., Kennedy, S. M. E. & Twitchin, B., 1979. (Krogsgaard-Larsen, P., Scheel- Kruger, J. & Kofod, H., eds) Academic Press, New York, pp. 149–168.
Krogsgaard-Larsen, P. & Johnston, G. A. R., 1978. J. Neurochem. 30: 1377–1382.
Enna, S. J. & Maggi, A., 1979. Life Sci. 24: 1727–1738.
Chrystal, E., Bey, P. & Rando, R. R., 1979. J. Neurochem. 32: 1501–1507.
Metcalf, B. W., 1979. Biochem. Pharmacol. 28: 1705–1712.
Schousboe, A., Thorbek, P., Hertz, L. & Krogsgaard-Larsen, P., 1979. J. Neurochem. 33: 181–189.
Brehm, L., Krogsgaard-Larsen, P. & Jacobsen, P., 1979. GABA-Neurotransmitters (Krogsgaard-Larsen, P., Scheel-Kruger, J. & Kofod, H., eds) Academic Press, New York, pp. 247–262.
Grandison, L. & Guidotti, A., 1977. Neuropharmacol. 16: 533–536.
DiMicco, J. A., Gale, K., Hamilton, B. & Gillis, R. A., 1979. Science 204: 1106–1109.
Scheel-Kruger, J., Arnt, J. & Magelund, G., 1977. Neurosci. Lett. 4: 351–354.
Grandison, L. & Guidotti, A., 1979. Endocrinology 105: 754–759.
Baxter, C. F., 1976. GABA in Nervous System Function. (Roberts, E., Chase, T. N. & Tower, D. B., eds) Raven Press, New York, pp. 61–87.
Iversen, L. L., 1978. Psychopharmacology: A Generation of Progress (Lipton, M. A., DiMascio, A. & Killam, K. F., eds) Raven press, New York, pp. 25–38.
Awapara, J., Landua, A. J., Fuerst, R. & Seale, B., 1950. J. Biol. Chem. 187: 35–39.
Roberts, E. & Frankel, S., 1950. J. Biol. Chem. 187: 55–63.
Bazemore, A. W., Elliott, K. A. C. & Florey, E., 1956. Nature 178: 1052–1053.
Bazemore, A. W., Elliott, K. A. C. & Florey, E., 1957. J. Neurochem. 1: 334–339.
Hayashi, T., 1959. J. Physiol. 145: 570–578.
Purpura, D. P., Girado, M., Smith, T. G., Callan, D. A. & Grundfest, H., 1959. J. Neurochem. 3: 238–268.
Eidelberg, E., Baxter, C. F., Roberts, E. & Saldias, C. A., 1960. Inhibition in the Nervous System and y-Amino-butyric Acid (Roberts, E., Baxter, C. F., Van Harreveld, A., Wiersma, C. A. G., Adey, R. & Killam, K. F., eds) Pergamon Press, New York, pp. 365–370.
Tower, D. B., 1960. Inhibition in the Nervous System and y-Aminobutyric Acid (Roberts, E., Baxter, C. F., Van Harreveld, A., Wiersma, C. A. G., Adey, R. & Killam, K. F. eds) Pergamon Press, New York, pp. 562–578.
Van Gelder, N. M. & Elliott, K. A. C., 1958. J. Neurochem. 3: 139–143.
Killam, K. F. & Bain, J. A., 1957. J. Pharmacol. Exp. Ther. 119: 255–262.
Coursin, D. B., 1960. Inhibition in the Nervous System and y-Aminobutyric Acid (Roberts, E., Baxter, C. F., Van Harreveld, A., Wiersma, C. A. G., Adey, W. R. & Killam, K. F. eds) Pergamon Press, New York, pp. 294–301.
Tower, D. B., 1958. Nutrition Rev. 16: 161–164.
Reilly, R. H., Killam, K. F., Jenney, E. H., Marshall, W. H., Tausig, T., Apter, N. S. & Pfeiffer, C. C., 1953. J. Am. Med. Assoc. 152: 1317–1321.
Kelly, J. S. & Beart, P. M., 1975. Handbook of Psychopharmacol. (Iversen, L. L., Iversen, S. D. & Snyder, S. H., eds.) Vol. 4, Plenum Press, New York, pp. 129–209.
Ryall, R. W., 1975. Handbook of Psychopharmacol. (Iversen, L. L., Iversen, S. D. & Snyder, S. H., eds.) Vol. 4, plenum Press, New York, pp. 83–128.
Baxter, C. F. & Roberts, E., 1959. Proc. Soc. Exp. Biol, and Med. 101: 811–815.
Baxter, C. F. & Roberts, E., 1961. J. Biol. Chem. 236: 3287–3294.
Tapia, R., 1975. Handbook of Psychopharmacol. (Iversen, L. L. Iversen, S. D. & Snyder, S. H., eds.), Vol. 4, Plenum Press, New York, pp. 1–58.
Roberts, E. & Eidelberg, E., 1960. Internati. Rev. Neurobiol. 2: 279–331.
Roberts, E., Wein, J. & Simonsen, D. G., 1964. Vitamins and Hormones 22: 503–559.
Cooper, J. R., Bloom, F. E. & Roth, R. H., 1978. The Biochemical Basis of neuropharmacology, Oxford Univ. Press, new York, pp. 223–258.
Wallach, D. P., 1961. Biochem. Pharmacol. 5: 323–331.
Tapia, R., Pasantes, H., Perez de la Mora, M., Ortega, B. G. & Massieu, G. H., 1967.
Loscher, W. & Frey, H.H., 1978. Biochem. Pharmacol. 27: 103–108.
Kuriyama, K., Roberts, E. & Rubenstein, M. K., 1966. Biochem. Pharmacol. 15: 221–236.
Wood, J. D. & Peesker, S. J., 1973. J. Neurochem. 20: 379–387.
Rando, R. R., 1974. Science 185: 320 - 324.
Fowler, L. J. & John, R. A., 1972. Biochem. J. 130: 569–573.
Jung, M. J. & Metealf, B. W., 1975. Biochem. Biophys. Res. Comm.
Rando, R. R. & Bangerter, F. W., 1976. J. Am. Chem. Soc. 98: 6762–6764.
Kobayashi, K., Miyazawa, S. & Terahara, A., 1976. Tetrahedron Lett. 7: 537–540.
Matsui, Y. & Deguchi, T., 1977. Life Sci. 20: 1291–1296.
Jung, M. J., Lippert, B., Metealf, B. W., Schechter, P. J., Bohlen, P. & Sjoerdsma, A., 1977. J. Neurochem. 28: 717–723.
Lippert, B., Metealf, B. W., Jung, M. J. & Casara, P., 1977. Eur. J. Biochem. 74: 441–445.
Schechter, P. J., Trainer, Y., Jung, M. J. & Bohlen, P., 1977. Eur. J. Pharmacol. 45: 319–328.
Loscher, W., 1980. J. Neurochem. 34: 1603–1608.
Godin, Y., Heiner, L., Mark, J. & Mandel, P., 1969. J. Neurochem. 16: 869–873.
Simler, S., Ciesielski, L., Maitre, M., Randrianarisoa, H. & Mandel, P., 1973. Biochem. Pharmacol. 22: 1701–1708.
Fowler, L. J., Beckford, J. & John, R. A., 1975. Biochem. Pharmacol. 24: 1267–1270.
Harvey, P. K. P., Bradford. H. F. & Davison, A. N., 1975. FEBS Lett. 52: 251–254.
Whittle, S. R. & Turner, A. J., 1978. J. Neurochem. 31: 1453–1459.
Kaufman, E. E., Nelson, T., Goochee, C. & Sokoloff, L., 1979. J. Neurochem. 32: 699–712.
Ciesielski, L., Maitre, M., Cash, C. & Mandel, P., 1975. Biochem. Pharmacol. 24: 1055–1058.
Dickinson, R. G., Harland, R. C., Ilias, A. M., Rodgers, R. M., Kaufman, S. N., Lynn, R. K. & Gerber, N., 1979. J. Pharmacol. Exp. Ther. 21 1: 583–595.
Albertson, T. E., Peterson, S. L., Stark, L. G. & Baselt, R. C., 1981. Neuropharmacol. 20: 95–97.
Schechter, P. J., Trainer, Y. & Grove, J., 1978. J. Neurochem. 31: 1325–1327.
Perry, T. L. & Hansen, S., 1978. J. Neurochem. 30: 679–684.
Kukino, K. & Deguchi, T., 1977. Chem. Pharm. Bull. 25: 2257–2261.
Perry, T. L. & Hansen, S., 1973. J. Neurochem. 21: 1167–1175.
Perry, T. L., Urquhart, N., Hansen, S. & Kennedy, J., 1974. J. Neurochem. 23: 443 - 445.
Perry, T. L., Kish, S. J. & Hansen, S., 1979. J. Neurochem. 32: 1641–1645.
Seiler, N., Bink, G. & Grove, J., 1979. Neurochem. Res. 4: 425–435.
Seiler, N., Bink, G. & Grove, J., 1980. Neuropharmacol. 19: 251–258.
Kuriyama, K., Roberts, E. & Rubinstein, M. K., 1966. Biochem. Pharmacol. 15: 221–236.
Wood, J. D. & Peesker, S. J., 1975. J. Neurochem. 25: 277–282.
Lust, W. D., kupferberg, H. J., Yonekawa, W. D., Penry, J. K., passoneau, J. V. & Wheaton, A. B., 1978. Molec. Pharmacol. 14: 347–356.
Horton, R. W., Anlezark, G. M., Sawaya, M. C. B. & Meldrum, B. S., 1977.
Goldstein, D. B., 1979. J. Pharmacol. Exp. Ther. 208: 223–227.
Meldrum, B. S., Anlezark, G. M., Ashton, C. G., Horton, R. W. & Sawaya, M. C. B., 1977. Post-traumatic Epilepsy, Pharmacological Prophylaxis of Epilepsy ( Majkowski, J., ed. ) pp. 139–153.
Stone, W. E., 1977. Epilepsia 18: 507–514.
Wood, J. D., Durham, J. S. & Peesker, S. J., 1977. Neurochem. Res. 2: 707–715.
Simon, D. & Penry, J. K., 1975. Epilepsia 16: 549–573.
Schechter, P. J., Tranier, Y., Jung, M. J., Sjoerdsma, A., 1977. J. Pharmacol. Exp. Ther. 201: 606–612.
Schechter, P.J. & Trainer, Y., 1977. Psychopharmacol. 54: 145–148.
Schechter, P. J. & Trainer, Y., 1978. Enzyme-Activated Irreversible Inhibitors (Seiler, N., Jung, M. J. & Koch- Weser, J., eds.) Elsevier, Amsterdam, pp. 149–162.
Loscher, W., 1980. N.S. Arch. Pharmacol. 315: 119–128.
Iadarola, M. J., Raines, A. R. & Gale, K., 1979. J. Neurochem. 33: 1119–1123.
Gale, K. & Iadarola, M. J., 1980. Science 208: 288–291.
Baxter, C. F. & Roberts, E., 1960. Proc. Soc. Exp. Biol. Med. 104: 426–427.
DaVanzo, J. P., Greig, M. E. & Cronin, M. A., 1961. Am. J. Physiol. 201: 833–837.
Roa, D. P., Tews, J. K. & Stone, W. E., 1964. Biochem. Pharmacol. 13: 477–487.
Murakami, Y., Abe, M. & Murakami, K., 1976. J. Neurochem. 26: 655–656.
Maynert, E. W. & Kaji, H. K., 1962. J. Pharmacol. Exp. Ther. 137: 114121.
Abe, M. & Matsuda, M., 1977. J. Biochem. 82: 195–200.
Wood, J. D., Russell, M. P., Kurylo, E. & Newstead, J. D., 1979. J. Neurochem. 33: 61–68.
Wood, J. D., 1975. Prog, in Neurobiol. 5: 77–95.
Okada, YU., Nitsch-Hassler, C., Kim, J. S., Bak, I. J. & Hassler, R., 1971. Exp. Brain Res. 14: 514–518.
Fahn, S. & Cote, L. J., 1968. J. Neurochem. 15: 209–213.
Tappaz, M. L., Brownstein, M. J. & Palkovits, M., 1976. Brain Res. 108: 371–379.
Massari, V. J., Gottesfeld, Z. & Jacobowitz, D. M., 1976. Brain Res. 118: 147–151.
Tappaz, M. L., Brownstein, M. J. & Kopin, I. J., 1977. Brain Res. 125: 109–121.
van der Heyden, J. A. M. & Korf, J., 1979. J. Neurochem. 33: 857–861.
Albers, R. W. & Brady, R. O., 1959. J. Biol. Chem. 234: 926–928.
Enna, S. J., Kuhar, M. J. & Snyder, S. H., 1975. Brain Res. 43: 168–174.
Placheta, P. & Karobath, M., 1979. Brain Res. 178: 580–583.
DeFeudis, F. V., 1977. Prog, in Neurobiol. 9: 123–145.
Kilpatrick, I. C., Starr, M. S., Fletcher, A., James, T. A. & MacLeod, N. K., 1980. Exp. Brain Res. 40: 45–54.
MacLeod, N. K., James, T. A., Kilpatrick, I. C. & Starr, M. S., 1980. Exp. Brain Res. 40: 55–61.
Vincent, S. R., Hattori, T. & McGeer, E. G., 1978. Brain Res. 151: 159–164.
Hertz, L., 1979. Prog. in Neurobiol. 13: 277–323.
Fonnum, F. & Walberg, F., 1973. Brain Res. 54: 115–127.
Schon, F. & Kelly, J. S., 1974. Brain Res. 66: 275–288.
Iversen, L. L., Dick, F., Kelly, J. S. & Schon, F., 1975. Metabolie Compartmentation and Neurotransmission (Berl, S., Clarke, D. D. & Schneider, D., eds) Plenum Press, new York, pp. 65–89.
Hutchinson, H. T., Werrbach, K., Vance, C. & Haber, B., 1974. Brain Res. 66: 265 - 274.
Lodge, D., Curtis, D. R. & Johnston, G. A. R., 1978. J. Neurochem. 31: 1525–1528.
Yarbrough, G. G., 1978. Can. J. Physiol. Pharmacol. 56: 443–446.
Frey, H. H., Popp, C. & Loscher, W., 1979. Neuropharmacol. 18: 581–590.
Kuriyama, K., 1976. GABA in Nervous System Function (Roberts, E., Chase, T. N. & Tower, D. B., eds) Raven Press, New York, pp. 187–196.
Barber, R. & Saito, K., 1976. GABA in Nervous System Function (Roberts, E., Chase, T. N. & Tower, D. B., eds) Raven Press, New York, pp. 113–132.
Van Gelder, N. M., 1965. J. Neurochem. 12: 231–237.
Hyde, J. C. & Robinson, N., 1974. J. Neurochem. 23: 365–367.
Schwarcz, R., Bennett, J. P. & Coyle, J. T., 1977. Ann. Neurol. 2: 299–303.
Wu, P. H., Durden, D. A. & Hertz, L., 1979. J. Neurochem. 32: 379–390.
Kohl, R. L., Quay, W. B. & Perez-Polo, J. R., 1980. J. Neurochem. 34: 1792–1795.
Toman, J. E P., Swinyard, E. A. & Goodman, L. S., 1946. J. Neurophysiol. 9: 231–239.
Woodbury, L. A. & Davenport, V. D., 1952. Arch. Int. Pharmacodyn. 92: 97–107.
Krall, R. L., Penry, J. K., White, B. G., Kupferberg, H. J. & Swinyard, E. A., 1978. Epilepsia 19: 409–428.
Coyle, J. T., Molliver, M. E. & Kuhar, M. J., 1978. J. Comp. Neurol. 180: 301–324.
Zaczek, R., Schwarcz, R. & Coyle, J. T., 1978. Brain Res. 152: 626–632.
Schwarcz, R. & Coyle, J. T., 1977. Brain Res. 127: 235–249.
Kim, J. S., Bäk, I. J., Hassler, R. & Okada, Y., 1971. Exp. Bain Res. 14: 95–104.
Hattori, T., McGeer, P. L., Fibiger, H. C. & McGeer, E. G., 1973. Brain Res. 54: 103–114.
Fonnum, F., Gottesfeld, Z. & Grofova, I., 1978. Brain Res. 143: 125–138.
Ribak, C. E., Vaughn, J. E. & Roberts, E., 1980. Brain Res. 192: 413–420.
Gale, K. & Iadarola, M. J., 1980. Brain Res. 183: 217–223.
Pycock, C. J., 1980. Neurosci. 5: 461–514.
Buu, N. T. & Van Gelder, N. M., 1974. Br. J. Pharmacol. 52: 401–406.
Knjevic, K. & Schwartz, S., 1968. Structure and Function of Inhibitory Neural Mechanisms (Von Euler, S., Skoglund, S. & Soderberg, U., eds.) Pergamon Press, New York, pp. 419–427.
Guidotti, A., Gale, K., Suria, A. & Toffano, G., 1979. Brain Res. 172: 566–571.
Waddington, J. L. & Cross, A. J., 1978. Nature 276: 618–620.
Iadarola, M. J. & Gale, K., 1979. Eur. J. Pharmacol. 59: 125–129.
Beart, P. M., Kelly, J. S. & Schon, F., 1974. Biochem. Soc. Transac. 2: 266–268.
Waniewski, R. A. & Suria, A., 1977. Life Sci. 21: 1129–1142.
Wood, J. D., Kurylo, E. & Newstead, J. D., 1978. Can. J. Biochem. 56: 667–672.
Sarhan, S. & Seiler, N., 1979. J. Neurosci. Res. 4: 398–421.
Bell, J. A. & Anderson, E. G., 1974. Neuropharmacol. 13: 885–894.
Gottesfeld, Z., Kelly, J. S. & Renaud, L. P., 1972. Brain Res. 11: 319–335.
Iadarola, M. J. & Gale, K., 1980. Brain Res. Bull. 5: Suppl. 2, pp. 13–19.
Palfreyman, M. G., Huot, S., Lippert, B. & Schechter, P. J., 1979. GABA-Neurotransmitters (Krogsgaard- Larsen, P., Scheel-Kruger, J. & Kofod, H., eds.) Academic Press, New York, pp. 432–446.
Gale, K. & Iadarola, M. J., 1980. Eur. J. Pharmacol. 68: 233–235.
Collins, R. C., McLean, M. & Olney, J., 1980. Life Sci. 27: 855–862.
Faeth, W. H., Walker, A. E. & Andy, O. J., 1954. Epilepsia, 3rd Series, 3: 37–48.
Casu, M. & Gale, K., 1981. Life Sci., 29: 681–688.
Nicklas, W. J., Nunez, R., Berl, S. & Duvoisin, R., 1979. J. Neurochem. 33: 839–844.
Casu, M. & Gale, K., 1981. J. Pharmacol. Exp. Ther. 217: 177–180.
Casu, M. & Gale, K., 1981. Fed. Proc., 40: 290.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1981 Martinus Nijhoff/Dr W. Junk Publishers, The Hague
About this chapter
Cite this chapter
Iadarola, M.J., Gale, K. (1981). Cellular compartments of GABA in brain and their relationship to anticonvulsant activity. In: Najjar, V.A. (eds) The Biological Effects of Glutamic Acid and Its Derivatives. Developments in Molecular and Cellular Biochemistry, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8027-3_20
Download citation
DOI: https://doi.org/10.1007/978-94-009-8027-3_20
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-8029-7
Online ISBN: 978-94-009-8027-3
eBook Packages: Springer Book Archive